Cited 0 times in
췌장암에서 혈청 CA 19-9와 CA 125의 유용성
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 정재복 | - |
dc.date.accessioned | 2021-09-28T07:54:39Z | - |
dc.date.available | 2021-09-28T07:54:39Z | - |
dc.date.issued | 1996-09 | - |
dc.identifier.issn | 1976-3573 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/183270 | - |
dc.description.abstract | Background/Aims: Trial to diagnose pancreatic cancer with CA 19-9 and CA125 has been continued, but study is rare to predict extensiveness of pancreatic cancer with CA 19-9 and CA 125. This study is conducted to evaluate the diagnostic accuracy of CA 19-9 and CA 125 for diagnosing pancreatic cancer and verify the usefulness of CA 19-9 and CA 125 to predict extensiveness of pancreatic cancer. Method: The serum level of CA 19-9 or CA 125 were determined by radioimmunometric assay in 218 patients. We analysed 67 cases of pancreatic cancer according to T, N, M stage, size, resectibility to verify the usefulness of CA 19-9 and CA 125 to predict extensiveness of pancreatic cancer. Result: The upper cutoff point of normal range was determined as 37 U/ml for CA 19-9 and 35 U/ml for CA 125 respectively. The sensitivity of CA 19-9 and CA 125 was 67.2% and 44.4% and specificity was 71.4% and 66.7% The sensitivity and specificity of combined analysis was 76.8% and 57.1% respectively. Positive rate of CA 19-9 in patient with pancreatic cancer, benign pancreatic disease, gastrointestinal cancer other than pancreatic cancer was 67.2%, 28.6%, 31.5% respectively and positive rate of CA 125 was 44.4%, 33.3%, 32.4%. The positive rate of CA 19-9 in patient with biliary cancer and stomach cancer was 52.4% and 25.0% and positive rate of CA 125 was 26.3% and 50.5% respectively. So positive rate of CA 19-9 in patient with pancreatic cancer only was higher than other gastrointestinal cancer statistically. The positive rate of CA 19-9 in T3 stage was higher than T1 and T2 stage and the positive rate of CA 125 was higher in unresectable pancreatic cancer statistically. But the positive rate of CA 19-9 and CA 125 was not related with size, lymph node involvement and distant metastasis. Conclusions: Combined analysis of CA 19-9 and CA 125 was more sensitive than single analysis. Serum CA 19-9 and CA 125 may be useful to predict resectibility of pancreatic cancer. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | Korean | - |
dc.publisher | 대한췌담도연구회 | - |
dc.relation.isPartOf | Korean Journal of Pancreas and Biliary Tract(대한췌담도연구회지) | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | 췌장암에서 혈청 CA 19-9와 CA 125의 유용성 | - |
dc.title.alternative | Serun CA 19-9 and CA 125 in Pancreatic Cancer | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | 이천균 | - |
dc.contributor.googleauthor | 정재복 | - |
dc.contributor.googleauthor | 송시영 | - |
dc.contributor.googleauthor | 강진경 | - |
dc.contributor.googleauthor | 박인서 | - |
dc.contributor.localId | A03706 | - |
dc.relation.journalcode | J03689 | - |
dc.identifier.eissn | 2288-0941 | - |
dc.subject.keyword | Pancreatic cancer | - |
dc.subject.keyword | CA 19-9 | - |
dc.subject.keyword | CA 125 | - |
dc.subject.keyword | Stage | - |
dc.subject.keyword | Resectibility | - |
dc.contributor.alternativeName | Chung, Jae Bock | - |
dc.contributor.affiliatedAuthor | 정재복 | - |
dc.citation.volume | 1 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 243 | - |
dc.citation.endPage | 250 | - |
dc.identifier.bibliographicCitation | Korean Journal of Pancreas and Biliary Tract (대한췌담도연구회지), Vol.1(2) : 243-250, 1996-09 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.